Vendor Drug Program Updates

Opioid-Related Clinical Prior Authorization Criteria Updates for Sept. 1

VDP regularly updates clinical prior authorization criteria to better align drug policies and prior authorization approval criteria with the latest information available on drug information packets, the federal or state regulations. Opioid-related prior authorizations are scheduled for revision on Sept. 1, 2020, to align with the uniform opioid policy. To learn more visit the VDP website.

Insulin Products Return to Non-Preferred Status on Sept. 18

VDP temporarily removed the non-preferred status on April 1 in response to reported drug shortages for insulin products in the "Hypoglycemics, Insulins" drug class. VDP will reverse this change in status because of sufficient availability in the market. Beginning Sept. 18, the Medicaid formulary will reflect the PDL status changes for all non-preferred insulin products. A list of affected NDCs and preferred PDL drugs are available from the VDP website.

Inhaled Glucocorticoids Products Return to Non-Preferred Status on Sept. 18

VDP temporarily removed the non-preferred status on April 1 in response to reported drug shortages for medications in the "Glucocorticoids, Inhaled" drug class. VDP will reverse this change in status because of sufficient availability in the market. Beginning Sept. 18, the formulary will reflect the PDL status changes for all non-preferred inhaled glucocorticoid products. A list of affected NDCs and preferred PDL drugs are available from the VDP website.